Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biomarin
Biomarin
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
Sat, 07/25/20 - 02:25 pm
FDA
GW Pharma
Epidiolex
filgotinib
Galapagos
Biomarin
valoctocogene roxaparvovec
With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel
Fierce Pharma
Wed, 06/24/20 - 11:21 pm
cell therapy
gene therapy
Novartis
Kite Pharma
Biomarin
Astellas
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioSpace
Wed, 06/17/20 - 10:00 pm
Biomarin
clinical trials
hemophilia A
valoctocogene roxaparvovec
BioMarin gene therapy shows sustained benefit in hemophilia A study
Seeking Alpha
Mon, 06/1/20 - 10:42 am
Biomarin
hemophilia A
clinical trials
gene therapy
valoctocogene roxaparvovec
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
Yahoo/PR Newswire
Sun, 05/3/20 - 07:53 pm
Biomarin
DiNAQOR
gene therapy
cardiomyopathy
BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020
Motley Fool
Thu, 04/30/20 - 10:25 am
Biomarin
earnings
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
Mon, 03/9/20 - 11:10 pm
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
BioMarin's Novel Treatment Promises to Disrupt Competitors
Motley Fool
Wed, 02/26/20 - 10:45 am
Biomarin
gene therapy
valrox
hemophilia A
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
Motley Fool
Thu, 02/20/20 - 11:41 pm
FDA
Biomarin
priority review
valrox
gene therapy
hemophilia A
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
Mon, 02/17/20 - 11:33 pm
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Forbes
Thu, 02/6/20 - 11:37 pm
Biomarin
valrox
gene therapy
hemophilia A
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
Motley Fool
Thu, 01/16/20 - 11:27 pm
Biomarin
JPMHC 2020
drug pricing
valrox
hemophilia
BioMarin sets gene therapy sights beyond hemophilia
BioPharma Dive
Mon, 01/13/20 - 11:40 pm
Biomarin
hemophilia
gene therapy
These 3 Biotech Stocks Could Be Top Stocks in 2020
Motley Fool
Sun, 01/12/20 - 11:19 pm
Biomarin
Iovance
Immunomedics
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
Yahoo/Benzinga
Sat, 01/11/20 - 11:02 pm
JPMHC 2020
Bristol-Myers Squibb
Vertex Pharmaceuticals
Biomarin
Regeneron
Biogen
Alexion
Gilead Sciences
Amgen
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
Thu, 12/19/19 - 01:11 pm
gene therapy
reimbursement
drug manufacturing
Bristol-Myers Squibb
Pfizer
Biomarin
Sarepta Therapeutics
Gilead Sciences
CAR-T
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Biopharma Dive
Thu, 12/12/19 - 10:52 am
Biomarin
hemophilia
hemophilia A
gene therapy
valoctocogene roxaparvovec
uniQure
hemophilia B
etranadez
Here's Why BioMarin Pharmaceutical Leapt 10.2% in November
Motley Fool
Wed, 12/4/19 - 10:19 am
Biomarin
R&D
gene therapy
Europe
The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict
Yahoo/Benzinga
Sun, 10/20/19 - 05:18 pm
earnings
Eli Lilly
Alexion
Gilead Sciences
Biomarin
Edwards Lifesciences
Baxter International
Integra LifeSciences
Phathom Pharmaceuticals
IPOs
Foamix
Eton Pharmaceuticals
Melinta Therapeutics
Ligand Pharmaceuticals
BioMarin talks down worries on gene therapy data differences
Biopharma Dive
Tue, 09/10/19 - 11:39 pm
Biomarin
gene therapy
hemophilia A
valrox
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »